Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INDV NASDAQ:KNSA NASDAQ:LEGN NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINDVIndivior$39.50-0.3%$32.24$10.63▼$41.00$4.83B0.92.23 million shs2.48 million shsKNSAKiniksa Pharmaceuticals International$58.60+2.9%$47.06$24.85▼$58.85$4.36B0.17919,882 shs394,279 shsLEGNLegend Biotech$28.12-1.6%$20.20$16.24▼$45.30$5.28B0.292.82 million shs2.60 million shsURGNUrogen Pharma$29.40+10.6%$20.59$3.42▼$30.45$1.30B1.58936,007 shs1.70 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINDVIndivior-2.49%+7.67%+29.96%+15.25%+244.50%KNSAKiniksa Pharmaceuticals International-2.23%+5.86%+16.33%+32.12%+112.66%LEGNLegend Biotech-1.35%+21.47%+58.81%+67.08%-9.22%URGNUrogen Pharma+1.30%+11.58%+47.48%+24.54%+162.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINDVIndivior$39.50-0.3%$32.24$10.63▼$41.00$4.83B0.92.23 million shs2.48 million shsKNSAKiniksa Pharmaceuticals International$58.60+2.9%$47.06$24.85▼$58.85$4.36B0.17919,882 shs394,279 shsLEGNLegend Biotech$28.12-1.6%$20.20$16.24▼$45.30$5.28B0.292.82 million shs2.60 million shsURGNUrogen Pharma$29.40+10.6%$20.59$3.42▼$30.45$1.30B1.58936,007 shs1.70 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINDVIndivior-2.49%+7.67%+29.96%+15.25%+244.50%KNSAKiniksa Pharmaceuticals International-2.23%+5.86%+16.33%+32.12%+112.66%LEGNLegend Biotech-1.35%+21.47%+58.81%+67.08%-9.22%URGNUrogen Pharma+1.30%+11.58%+47.48%+24.54%+162.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINDVIndivior 3.00Buy$39.33-0.42% DownsideKNSAKiniksa Pharmaceuticals International 2.67Moderate Buy$60.863.85% UpsideLEGNLegend Biotech 2.67Moderate Buy$58.31107.35% UpsideURGNUrogen Pharma 2.78Moderate Buy$35.2519.90% UpsideCurrent Analyst Ratings BreakdownLatest URGN, LEGN, INDV, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $40.005/6/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/6/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/6/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/29/2026KNSAKiniksa Pharmaceuticals International Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $64.004/29/2026KNSAKiniksa Pharmaceuticals International CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $60.004/29/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$58.00 ➝ $59.004/29/2026KNSAKiniksa Pharmaceuticals International Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $57.004/28/2026KNSAKiniksa Pharmaceuticals International Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$58.00 ➝ $71.004/24/2026URGNUrogen Pharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINDVIndivior$1.24B3.89$2.71 per share14.56($1.18) per share-33.47KNSAKiniksa Pharmaceuticals International$677.56M6.62$0.82 per share71.72$7.91 per share7.41LEGNLegend Biotech$1.03B5.05N/AN/A$5.43 per share5.18URGNUrogen Pharma$109.79M13.05N/AN/A($2.55) per share-11.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINDVIndivior$210M$1.9520.2610.73N/A19.44%-219.26%29.40%N/AKNSAKiniksa Pharmaceuticals International$59.01M$0.9065.1134.47N/A9.69%13.26%9.86%N/ALEGNLegend Biotech-$296.80M-$0.80N/A16.74N/A-28.86%-21.93%-13.21%5/12/2026 (Estimated)URGNUrogen Pharma-$153.49M-$2.75N/A34.19N/A-94.83%N/A-62.85%N/ALatest URGN, LEGN, INDV, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026LEGNLegend Biotech-$0.02N/AN/AN/A$306.51 millionN/A5/6/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 million3/31/2026Q1 2026INDVIndiviorN/A$0.96N/A$3.45N/A$317.00 million3/11/2026Q4 2025LEGNLegend Biotech-$0.17$0.01+$0.18-$0.16$310.21 million$306.30 million3/2/2026Q4 2025URGNUrogen Pharma-$0.66-$0.54+$0.12-$0.54$39.92 million$37.84 million2/27/2026Q4 2025INDVIndivior$0.65$0.82+$0.17$3.95$305.62 million$358.00 million2/24/2026Q4 2025KNSAKiniksa Pharmaceuticals International$0.29$0.17-$0.12$0.17$200.86 million$202.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINDVIndiviorN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINDVIndiviorN/A0.860.66KNSAKiniksa Pharmaceuticals InternationalN/A3.793.33LEGNLegend BiotechN/A1.961.91URGNUrogen PharmaN/A4.693.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINDVIndivior60.33%KNSAKiniksa Pharmaceuticals International53.95%LEGNLegend Biotech70.89%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipINDVIndivior0.74%KNSAKiniksa Pharmaceuticals International53.48%LEGNLegend Biotech0.02%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableKNSAKiniksa Pharmaceuticals International22076.54 million35.60 millionOptionableLEGNLegend Biotech2,965184.96 million184.92 millionOptionableURGNUrogen Pharma20048.72 million46.43 millionOptionableURGN, LEGN, INDV, and KNSA HeadlinesRecent News About These CompaniesUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2026 Earnings Call TranscriptMay 8 at 2:11 PM | insidermonkey.comUrogen Pharma (NASDAQ:URGN) Sets New 1-Year High Following Analyst UpgradeMay 8 at 11:19 AM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given New $40.00 Price Target at OppenheimerMay 8 at 5:31 AM | americanbankingnews.comUroGen Pharma Earnings Call Highlights ZUSDURI SurgeMay 7 at 9:51 PM | tipranks.comUroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027May 7 at 3:59 PM | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Oppenheimer Analyst SaysMay 7 at 9:16 AM | marketbeat.comUroGen Pharma to Present at Upcoming Investor ConferencesMay 7 at 8:00 AM | globenewswire.comUrogen Pharma Q1 Earnings Call HighlightsMay 7 at 4:17 AM | marketbeat.comUroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call TranscriptMay 6 at 6:10 PM | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 6 at 3:27 PM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Trading Up 14% on Better-Than-Expected EarningsMay 6 at 2:33 PM | marketbeat.comUrogen Pharma (URGN) Reports Q1 Loss, Beats Revenue EstimatesMay 6 at 10:30 AM | zacks.comUroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and HighlightsMay 6 at 8:00 AM | globenewswire.comUrogen Pharma (URGN) Projected to Post Earnings on WednesdayMay 2, 2026 | americanbankingnews.comUrogen Pharma (URGN) Projected to Post Quarterly Earnings on WednesdayMay 2, 2026 | marketbeat.comUroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026April 29, 2026 | globenewswire.comHC Wainwright Predicts Urogen Pharma Q1 EarningsApril 27, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Rating Increased to Strong-Buy at Jefferies Financial GroupApril 25, 2026 | marketbeat.comHC Wainwright Predicts Urogen Pharma Q3 EarningsApril 24, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Trading Up 9% - Should You Buy?April 20, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by AnalystsApril 20, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeURGN, LEGN, INDV, and KNSA Company DescriptionsIndivior NASDAQ:INDV$39.50 -0.10 (-0.25%) Closing price 04:00 PM EasternExtended Trading$40.10 +0.60 (+1.52%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Kiniksa Pharmaceuticals International NASDAQ:KNSA$58.60 +1.67 (+2.93%) Closing price 04:00 PM EasternExtended Trading$58.60 -0.01 (-0.01%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Legend Biotech NASDAQ:LEGN$28.12 -0.45 (-1.58%) Closing price 04:00 PM EasternExtended Trading$28.04 -0.08 (-0.30%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Urogen Pharma NASDAQ:URGN$29.40 +2.81 (+10.57%) Closing price 04:00 PM EasternExtended Trading$29.49 +0.09 (+0.32%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
